Education and Training
Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer
Primary:
To determine the duration of use of zoledronic acid in improving Bone mineral density in patients with prostate cancer who are on hormones intermittently.
Secondary Objectives:
To describe the safety and tolerability at this dose and schedule
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: zoledronic acid
Eligibility
Inclusion Criteria:Patients: Who are 18 years of age and older Who have histologically
documented adenocarcinoma of prostate Who are currently receiving LHRH agonists KPS greater
than 80%Life expectancy greater than 6 months Provide written consent pursuant to
regulatory requirements prior to initiation of study procedure Exclusion Criteria:Exclusion
Criteria: Patients: Any patient requiring continuous LHRH Any patient who has had an
orchiectomy Any patient with painful bone metastases Who have received chemotherapy for
prostate cancer Who have a abnormal serum creatine >2.5 Receiving any investigational drug
within the last 28 days Severe uncontrolled infection, diabetes, cardiac disease Patients
with fragility fractures, hyperparathyroidism, Pagets renal osteodystrophy will be excluded
History of non compliance to medical regimens or unwillingness to return for medical visits
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
Male
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Denise Haas
6507361252
Not Recruiting